#### IDEXX LABORATORIES INC /DE

Form 4

February 04, 2014

## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB Number:

3235-0287

0.5

Expires: January 31, 2005

**OMB APPROVAL** 

Estimated average burden hours per

burden hours per response...

subject to Section 16. Form 4 or Form 5 obligations

may continue.

See Instruction

if no longer

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * AYERS JONATHAN W			2. Issuer Name <b>and</b> Ticker or Trading Symbol IDEXX LABORATORIES INC /DE [IDXX]	5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)		
(Last) ONE IDEXX	(First)  DRIVE	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/31/2014	_X_ Director10% Owner _X_ Officer (give title Other (specify below)  Chairman, President & CEO		
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person		
WESTBROOM	K, ME 04092	2		Form filed by More than One Reporting Person		

(City)	(State)	(Zip) Tak	ole I - Non-	-Derivative	e Secu	rities Acquire	ed, Disposed of, o	or Beneficially	Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities Acquired (A) or TransactionDisposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	or (D)	Price	(Instr. 3 and 4)		
Common Stock	01/31/2014		M	13,000	A	\$ 25.45	390,271 <u>(1)</u>	D	
Common Stock	01/31/2014		M	7,000	A	\$ 41.935	397,271	D	
Common Stock	01/31/2014		M	25,000	A	\$ 50	422,271	D	
Common Stock	01/31/2014		S(2)	12,589	D	\$ 112.4482 (3)	409,682	D	
Common Stock	01/31/2014		S(2)	9,900	D	\$ 113.3537	399,782	D	

### Edgar Filing: IDEXX LABORATORIES INC /DE - Form 4

					<u>(4)</u>			
Common Stock	01/31/2014	S(2)	16,600	D	\$ 114.1165 (5)	383,182	D	
Common Stock	02/03/2014	M	15,072	A	\$ 25.45	398,254	D	
Common Stock	02/03/2014	M	8,616	A	\$ 41.935	406,870	D	
Common Stock	02/03/2014	M	25,000	A	\$ 50	431,870	D	
Common Stock	02/03/2014	S(2)	11,300	D	\$ 110.3855 <u>(6)</u>	420,570	D	
Common Stock	02/03/2014	S(2)	19,400	D	\$ 111.3895 <u>(7)</u>	401,170	D	
Common Stock	02/03/2014	S(2)	2,986	D	\$ 112.654 (8)	398,184	D	
Common Stock	02/03/2014	S(2)	8,519	D	\$ 113.2903	389,665	D	
Common Stock						49,000	I	By Ayers Family Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exerc	cisable and	7. Title and A	Amour
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	orDerivative	Expiration D	ate	Underlying S	Securit
Security	or Exercise		any	Code	Securities	(Month/Day/	Year)	(Instr. 3 and	4)
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired (A)				
	Derivative				or Disposed of				
	Security				(D)				
					(Instr. 3, 4,				
					and 5)				
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amo or Num of Sh
				code v	(11) (D)				OI SII
	\$ 25.45	01/31/2014		M	13,000	(10)	02/04/2014		13,0

(9-02)

#### Edgar Filing: IDEXX LABORATORIES INC /DE - Form 4

Non-Qualified Stock Option (right to buy)							Common Stock	
Non-Qualified Stock Option (right to buy)	\$ 41.935	01/31/2014	M	7,000	<u>(11)</u>	02/13/2014	Common Stock	7,0
Non-Qualified Stock Option (right to buy)	\$ 50	01/31/2014	M	25,000	(12)	02/13/2014	Common Stock	25,0
Non-Qualified Stock Option (right to buy)	\$ 25.45	02/03/2014	M	15,072	(10)	02/04/2014	Common Stock	15,0
Non-Qualified Stock Options (right to buy)	\$ 41.935	02/03/2014	M	8,616	<u>(11)</u>	02/13/2014	Common Stock	8,6
Non-Qualified Stock Options (right to buy)	\$ 50	02/03/2014	M	25,000	(12)	02/13/2014	Common Stock	25,0

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
·r· · · · · · · · · · · · · · · · · · ·	Director	10% Owner	Officer	Other		
AYERS JONATHAN W ONE IDEXX DRIVE WESTBROOK, ME 04092	X		Chairman, President & CEO			

## **Signatures**

Jennifer L. Panciocco, Attorney-in Fact for Jonathan W. Ayers 02/04/2014

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 60 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 12/31/2013.
- (2) The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 02/28/2013.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from \$111.8450 to \$112.8200, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3, 4, 5, 6, 7, 8 and 9 to this Form 4.
- (4) The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from \$112.8500 to \$113.8300, inclusive.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from \$113.8500 to \$114.3600, inclusive.

Reporting Owners 3

#### Edgar Filing: IDEXX LABORATORIES INC /DE - Form 4

- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from \$109.8600 to \$110.8500, inclusive.
- (7) The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from \$110.8600 to \$111.8450 inclusive.
- (8) The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from \$111.9136 to \$112.9000, inclusive.
- (9) The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from \$112.9200 to \$113.6900, inclusive.
- (10) Grant of options to buy shares of common stock becomes exercisable as to 22,000 shares on 02/05/2005, 02/05/2006, 02/05/2007 and 02/05/2008, and the remaining 18,072 shares on 02/05/2009.
- Grant of options to buy shares of common stock becomes exercisable as to 12,000 shares on 02/14/2008, 02/14/2009, 02/14/2010 and 02/14/2011, and the remaining 9,616 shares on 02/14/2012.
- (12) Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (02/14/2008) of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.